Immunogenicity 14781
Sample ID
3903
Response
Negative
Tumor Type
Melanoma
Gene Symbol
OLFML2B
Transcript ID
uc010pkq.2
HLA INFO
A*24:02
TCR INFO
No TCR info found!
Full length protein sequence (751 aa)
MAKPR
1
LLVLY
6
FALIV
11
VPAWV
16
SSIVL
21
TGTSE
26
PPDAQ
31
TVAPA
36
EDETL
41
QNEAD
46
NQENV
51
LSQLL
56
GDYDK
61
VKAMS
66
EGSDC
71
QCKCV
76
VRPLG
81
RDACQ
86
RINAG
91
ASRKE
96
DFYTV
101
ETITS
106
GSSCK
111
CACVA
116
PPSAL
121
NPCEG
126
DFRLQ
131
KLREA
136
DSQDL
141
KLSTI
146
IDMLE
151
GAFYG
156
LDLLK
161
LHSVT
166
TKLVG
171
RVDKL
176
EEEVS
181
KNLTK
186
ENEQI
191
KEDME
196
EIRTE
201
MNKRG
206
KENCS
211
ENILD
216
SMPDI
221
RSALQ
226
RDAAA
231
AYAHP
236
EQYEE
241
RFLQE
246
ETVSQ
251
QINSI
256
ELLQT
261
RPLAL
266
PEVVK
271
SQRPL
276
QRQVH
281
LRGRP
286
ASQPT
291
VIRGI
296
TYYKA
301
KVSEE
306
ENDIE
311
EQQDE
316
FFSGD
321
NGVDL
326
LIEDQ
331
LLRHN
336
GLMTS
341
VTRRP
346
AATRQ
351
GHSTA
356
VTSDL
361
NARTA
366
PWSSA
371
LPQPS
376
TSDPS
381
IANHA
386
SVGPT
391
LQTTS
396
VSPDP
401
TRESV
406
LQPSP
411
QVPAT
416
TVAHT
421
ATQQP
426
AAPAP
431
PAVSP
436
REALM
441
EAMHT
446
VPVPP
451
TTVRT
456
DSLGK
461
DAPAG
466
WGTTP
471
ASPTL
476
SPEEE
481
DDIRN
486
VIGRC
491
KDTLS
496
TITGP
501
TTQNT
506
YGRNE
511
GAWMK
516
DPLAK
521
DERIY
526
VTNYY
531
YGNTL
536
VEFRN
541
LENFK
546
QGRWS
551
NSYKL
556
PYSWI
561
GTGHV
566
VYNGA
571
FYYNR
576
AFTRN
581
IIKYD
586
LKQRY
591
VAAWA
596
MLHDV
601
AYEEA
606
TPWRW
611
QGHSD
616
VDFAV
621
DENGL
626
WLIYP
631
ALDDE
636
GFSQE
641
VIVLS
646
KLNAA
651
DLSTQ
656
KETTW
661
RTGLR
666
RNFYG
671
NCFVI
676
CGVLY
681
AVDSY
686
NQRNA
691
NISYA
696
FDTHT
701
NTQIV
706
PRLLF
711
ENEYS
716
YTTQI
721
DYNPK
726
DRLLY
731
AWDNG
736
HQVTY
741
HVIFA
746
Y
751
Mutation Information
DNA mutation:
None
Peptide Range:
514 ~ 538
Mut AA position:
None (None in Wild Type peptide)
Alignment
Wild Type:
"NEGAWMKDPLAKDERIYVTNYYYGN
||||||||||||.||||||||||||
Mutant:
NEGAWMKDPLAKNERIYVTNYYYGN"
Nat Med, 2016
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patientsGene Name (from Reference) OLFML2B
Checkpoint
Blockade
None
ACT
None
Vaccination
None
Curative
Effect
None
minimal_peptide
None
Antigen
Type
TMG RNA
T-cell
Source
PBMCs
APC
Type
autologous DCs
Assay
IFNg ELISPOT assay